AXSM
NASDAQAxsome Therapeutics Inc.
Price$229.98-3.91 (-1.67%)
01:30 PM07:45 PM
News · 26 weeks80-74%
2026-01-182026-07-12
Mix5190d
- Insider20(39%)
- SEC Filings15(29%)
- Other12(24%)
- Earnings4(8%)
Latest news
25 items- SECAxsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)
- PRAxsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in NarcolepsyFDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. The FDA also indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. About Narcolepsy Narcolepsy is a serious
- PRAxsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2026 on Monday, August 10, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presenta
- PRAxsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-2 Phase 3 trial evaluating solriamfetol as a treatment for children with attention deficit hyperactivity disorder (ADHD). FOCUS-2 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfeto
- INSIDERChief Executive Officer Tabuteau Herriot exercised 49,666 shares at a strike of $4.95 and sold $11,932,256 worth of shares (49,666 units at $240.25) as part of a pre-agreed trading plan (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- SECSEC Form 144 filed by Axsome Therapeutics Inc.144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
- PRAxsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity disorder (ADHD). FOCUS-3 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to less than 18 years with ADHD. Approximately 468 patients will be randomize
- PRAxsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness MonthNEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining patients, caregivers, and advocacy organizations in raising awareness of brain health and the impact of Alzheimer's disease during Alzheimer's & Brain Awareness Month. "Nearly everyone knows brain health is important, but many people aren't sure what steps to take to protect it," said Wendy Vizek, Senior Vice President, Community Engagement and Field Operations at the Alzheimer's Association. "That's why Alzheimer's & Brain Awareness Month in June is such an important mom
- PRAxsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data on AXS-12 and solriamfetol at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 14-17, 2026, in Baltimore, Maryland. Details of the presentations are as follows: Title: Cognitive and Functional Outcomes from the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with CataplexyPresentation Date and Time: Monday, June 15, 10:00 - 11:45 a.m. ETLead Author: Bruce Cor
- INSIDERDirector Jeffs Roger sold $141,656 worth of shares (572 units at $247.65) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 58,367 units (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- SECSEC Form 144 filed by Axsome Therapeutics Inc.144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
- INSIDERDirector Saad Mark E converted options into 1,429 shares, increasing direct ownership by 14% to 11,431 units (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERDirector Jeffs Roger converted options into 1,429 shares, increasing direct ownership by 2% to 58,939 units (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERDirector Mahony Susan converted options into 1,429 shares and sold $145,017 worth of shares (600 units at $241.69) as part of a pre-agreed trading plan (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERDirector Coleman Mark converted options into 1,429 shares and sold $160,107 worth of shares (643 units at $249.00) as part of a pre-agreed trading plan, increasing direct ownership by 3% to 30,389 units (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- SECSEC Form 144 filed by Axsome Therapeutics Inc.144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
- SECSEC Form 144 filed by Axsome Therapeutics Inc.144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
- SECSEC Form 144 filed by Axsome Therapeutics Inc.144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
- SECAxsome Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)
- SECAxsome Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)
- INSIDERSEC Form 4 filed by Director Coleman Mark4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by Director Mahony Susan4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERChief Executive Officer Tabuteau Herriot exercised 49,670 shares at a strike of $4.95 and sold $11,970,967 worth of shares (49,670 units at $241.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERChief Financial Officer Pizzie Nick exercised 33,000 shares at a strike of $3.50 and sold $7,922,970 worth of shares (33,000 units at $240.09) as part of a pre-agreed trading plan (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by Director Saad Mark E4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
AXSM FAQ
7 questionsWhat does Axsome Therapeutics Inc. do?
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for...Where does AXSM stock trade?
Axsome Therapeutics Inc. (AXSM) is listed on NASDAQ.What sector and industry is AXSM in?
Axsome Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Axsome Therapeutics Inc. go public?
Axsome Therapeutics Inc. (AXSM) completed its IPO in 2015.What are analysts saying about AXSM?
Axsome Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-02-24.What companies are similar to AXSM?
Notable peers in the same industry include RLAY (Relay Therapeutics Inc.), CAPR (Capricor Therapeutics Inc.), FMTX (Forma Therapeutics Holdings Inc.), TNYA (Tenaya Therapeutics Inc.), ODT (Odonate Therapeutics Inc.). Compare AXSM side-by-side with any of them on Quantisnow.How can I track AXSM on Quantisnow?
Quantisnow aggregates Axsome Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AXSM to receive live email and push alerts on every new disclosure.